Log in
NASDAQ:FOMX

Menlo Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$2.99
0.00 (0.00 %)
(As of 03/9/2020)
Add
Compare
Today's Range
$2.99
Now: $2.99
$2.99
50-Day Range
$2.99
MA: $2.99
$2.99
52-Week Range
$1.97
Now: $2.99
$4.84
VolumeN/A
Average Volume518,350 shs
Market Capitalization$184.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.
Read More
Menlo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.77 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FOMX
CUSIPN/A
Phone972-8931-6233
Employees80

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.60 million
Book Value$1.70 per share

Profitability

Net Income$-74,160,000.00

Miscellaneous

Market Cap$184.12 million
Next Earnings DateN/A
OptionableOptionable

Receive FOMX News and Ratings via Email

Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Menlo Therapeutics (NASDAQ:FOMX) Frequently Asked Questions

What stocks does MarketBeat like better than Menlo Therapeutics?

Wall Street analysts have given Menlo Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Menlo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc. (NASDAQ:FOMX) posted its quarterly earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.07.
View Menlo Therapeutics' earnings history
.

Who are some of Menlo Therapeutics' key competitors?

What other stocks do shareholders of Menlo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), OPKO Health (OPK) and Pfizer (PFE).

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the following people:
  • Mr. David T. Domzalski, CEO & Director (Age 52)
  • Mr. Ilan Hadar M.B.A., MBA, CFO & Country Mang. (Age 50)
  • Ms. Mutya Harsch, Gen. Counsel & Chief Legal Officer (Age 44)
  • Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)
  • Dr. Iain A. Stuart, Chief R&D Officer (Age 46)

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "FOMX."

What is Menlo Therapeutics' stock price today?

One share of FOMX stock can currently be purchased for approximately $2.99.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $184.12 million and generates $3.60 million in revenue each year. The specialty pharmaceutical company earns $-74,160,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Menlo Therapeutics employs 80 workers across the globe.

What is Menlo Therapeutics' official website?

The official website for Menlo Therapeutics is www.foamix.com.

How can I contact Menlo Therapeutics?

Menlo Therapeutics' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.